<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">russjcardiol</journal-id><journal-title-group><journal-title xml:lang="ru">Российский кардиологический журнал</journal-title><trans-title-group xml:lang="en"><trans-title>Russian Journal of Cardiology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1560-4071</issn><issn pub-type="epub">2618-7620</issn><publisher><publisher-name>«SILICEA-POLIGRAF» LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.15829/1560-4071-2018-8-13-20</article-id><article-id custom-type="elpub" pub-id-type="custom">russjcardiol-2866</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLES</subject></subj-group></article-categories><title-group><article-title>ПОВЫШЕННЫЙ ТИТР IgM АУТОАНТИТЕЛ К ЛИПОПРОТЕИДУ(a) КАК АНТИАТЕРОГЕННЫЙ ФАКТОР У ПАЦИЕНТОВ С ТЯЖЕЛОЙ ГИПЕРХОЛЕСТЕРИНЕМИЕЙ</article-title><trans-title-group xml:lang="en"><trans-title>RAISED IgM AUTOANTIBODY TITER TO LIPOPROTEIDE(A) AS ANTIATHEROGENIC FACTOR IN SEVERE HYPERCHOLESTEROLEMIA PATIENTS</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0682-8699</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Клесарева</surname><given-names>Е. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Klesareva</surname><given-names>E. A.</given-names></name></name-alternatives><bio xml:lang="ru"/><bio xml:lang="en"/><email xlink:type="simple">hea@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8909-8662</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Афанасьева</surname><given-names>О. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Afanasieva</surname><given-names>O. I.</given-names></name></name-alternatives><bio xml:lang="ru"/><bio xml:lang="en"/><email xlink:type="simple">Afanasieva@cardio.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3970-7498</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кононова</surname><given-names>Е. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Kononova</surname><given-names>E. V.</given-names></name></name-alternatives><bio xml:lang="ru"/><bio xml:lang="en"/><email xlink:type="simple">Elena24936@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6742-5976</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Уткина</surname><given-names>Е. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Utkina</surname><given-names>E. A.</given-names></name></name-alternatives><bio xml:lang="ru"/><bio xml:lang="en"/><email xlink:type="simple">utkelena@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1518-6552</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ежов</surname><given-names>М. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Ezhov</surname><given-names>M. V.</given-names></name></name-alternatives><bio xml:lang="ru"/><bio xml:lang="en"/><email xlink:type="simple">marat_ezhov@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7273-6979</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Балахонова</surname><given-names>Т. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Balakhonova</surname><given-names>T. V.</given-names></name></name-alternatives><bio xml:lang="ru"/><bio xml:lang="en"/><email xlink:type="simple">tvbdoc@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5725-3805</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Афанасьева</surname><given-names>М. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Afanasieva</surname><given-names>M. I.</given-names></name></name-alternatives><bio xml:lang="ru"/><bio xml:lang="en"/><email xlink:type="simple">afanasievabiocomerts@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5944-6427</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Покровский</surname><given-names>С. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Pokrovsky</surname><given-names>S. N.</given-names></name></name-alternatives><bio xml:lang="ru"/><bio xml:lang="en"/><email xlink:type="simple">dr.pokrovsky@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru">ФГБУ Национальный медицинский исследовательский центр кардиологии Минздрава России<country>Россия</country></aff><aff xml:lang="en">National Medical Research Center of Cardiology of the Ministry of Health<country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru">Федеральное государственное ФГБУ Национальный медицинский исследовательский центр кардиологии Минздрава России<country>Россия</country></aff><aff xml:lang="en">National Medical Research Center of Cardiology of the Ministry of Health<country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2018</year></pub-date><pub-date pub-type="epub"><day>09</day><month>09</month><year>2018</year></pub-date><volume>0</volume><issue>8</issue><fpage>13</fpage><lpage>20</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Клесарева Е.А., Афанасьева О.И., Кононова Е.В., Уткина Е.А., Ежов М.В., Балахонова Т.В., Афанасьева М.И., Покровский С.Н., 2018</copyright-statement><copyright-year>2018</copyright-year><copyright-holder xml:lang="ru">Клесарева Е.А., Афанасьева О.И., Кононова Е.В., Уткина Е.А., Ежов М.В., Балахонова Т.В., Афанасьева М.И., Покровский С.Н.</copyright-holder><copyright-holder xml:lang="en">Klesareva E.A., Afanasieva O.I., Kononova E.V., Utkina E.A., Ezhov M.V., Balakhonova T.V., Afanasieva M.I., Pokrovsky S.N.</copyright-holder><license license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://russjcardiol.elpub.ru/jour/article/view/2866">https://russjcardiol.elpub.ru/jour/article/view/2866</self-uri><abstract><sec><title>Цель</title><p>Цель. Изучить связь Лп(а), подфракций атерогенных липопротеидов и титров специфических аутоантител (аутоАт) с наличием и тяжестью поражения сонных артерий (СА) у статин-наивных пациентов с тяжелой гиперхолестеринемией.</p></sec><sec><title>Материал и методы</title><p>Материал и методы. В исследование были включены 133 статин-наивных пациента в возрасте от 18 до 75 лет с отсутствием клинических признаков ИБС на фоне впервые выявленной тяжелой гиперхолестеринемии (общий холестерин выше 7,5 ммоль/л  и/или холестерин липопротеидов низкой плотности более 4,9 ммоль/л) с результатами ультразвукового дуплексного сканирования СА. Всем пациентам измеряли концентрацию Лп(а), липидного спектра, субфракционный состав апоВ-100-содержащих липопротеидов и титр аутоАт против них.</p></sec><sec><title>Результаты</title><p>Результаты. В соответствии с результатами дуплексного сканирования СА больные были разделены на две группы: контрольная группа (n=76) без атеросклероза СА, пациенты со стенозом СА 20% и выше (n=57) составили основную группу. Больные с атеросклерозом СА были старше, чем пациенты контрольной группы, по другим клиническим характеристикам и показателям липидного спектра отличий не было. Титр аутоАт класса IgM, специфичных к Лп(а) и его окисленным модификациям, был достоверно ниже в группе пациентов с атеросклерозом СА по сравнению с контрольной группой. Степень стенозирования СА у пациентов с тяжелой гиперхолестеринемий была положительно связана с возрастом (r=0,24, p=0,005) и обратно - с титром аутоАт класса IgM к апоВ100-содержащим липопротеидам и (r=-0,28 и r=-0,26, p&lt;0,005). Также была выявлена прямая взаимосвязь степени стенозирования СА с подфракциями липопротеидов промежуточной плотности среднего размера (ЛПП-B) (r=0,21, p=0,032). Титр аутоАт против Лп(а) был независимым предиктором степени поражения СА вне зависимости от возраста и традиционных факторов риска по данным многофакторного регрессионного анализа. По данным ROC-анализа с наибольшей диагностической ценностью (площадь под кривой AUC=0,68) уровень аутоАт класса IgM к Лп(а) менее 0,083 лаб.ед. с чувствительностью 40% и специфичностью 88% был связан с поражением общих СА.  </p></sec><sec><title>Заключение</title><p>Заключение. У пациентов с тяжелой гиперхолестеринемией Лп(а) является аутоантигеном и IgM аутоантитела к Лп(а) играют антиатерогенную роль.  </p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Aim</title><p>Aim. To investigate on the relation of lipoproteide(a) (Lpa), subfractions of atherogenic lipoproteides and titers of specific autoantibodies (autoAb) with the presence and severity of carotid arteries (CA) lesion in statin-naïve patients with severe hypercholesterolemia.</p></sec><sec><title>Material and methods</title><p>Material and methods. To the study, 133 statin-naïve patients included, age 18 to 75 y.o., with absent clinical signs of coronary heart disease, and with first time diagnosed severe hypercholesterolemia (total cholesterol &gt;7,5 mM/L and/or low density lipoproteides cholesterol &gt;4,9 mM/L) with ultrasound duplex scan data of CA. All patients underwent measurement of Lpa concentration, lipid profile, subfractional content of apoB-100-containing lipoproteides and autoAb titer against them.</p></sec><sec><title>Results</title><p>Results. According to the data from duplex CA scan, patients were selected to 2 groups: control group (n=76) with no CA atherosclerosis; main group — patients with CA stenosis &gt;20% (n=57). The participants of main group were older than controls, with no other clinical or lipid profile differences. Titre of autoAb IgM specific for Lpa and its oxidized modifications was significantly lower in CA atherosclerosis comparing to controls. The grade of CA stenosis in severe hypercholesterolemia patients positively correlated with age (r=0,24, p=0,005) and negatively — with autoAb IgM to apoB100-containing lipoproteides (r=-0,28 and r=-0,26, p&lt;0,005). Also, a correlation found for CA stenosis grade with subfractions of intermediate density lipoproteides of moderate size (r=0,21, p=0,032). AutoAb titre against Lpa was an independent predictor of CA lesion severity regardless the age and traditional risk factors by the data from multifactorial regression. By ROCanalysis with the highest diagnostic value (square under AUC =0,68) the level of autoAb IgM to Lpa lower than 0,083 lab. units, with sensitivity 40% and specificity 88% is related to the lesion of common CA.</p></sec><sec><title>Conclusion</title><p>Conclusion. In patients with severe hypercholesterolemia Lpa is an autoantigen, and IgM autoantibodies to Lpa play antiatherogenic role.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>атеросклероз</kwd><kwd>липопротеид(а)</kwd><kwd>аутоантитела</kwd><kwd>иммуноглобулины М</kwd><kwd>стеноз сонных артерий</kwd></kwd-group><kwd-group xml:lang="en"><kwd>atherosclerosis</kwd><kwd>lipoproteide (a)</kwd><kwd>autoantibodies</kwd><kwd>immunoglobulines M</kwd><kwd>stenosis of carotid arteries</kwd></kwd-group><funding-group xml:lang="ru"><funding-statement>Работа выполнена при поддержке «ООО Амджен», «Санофи», «АстраЗенека» и  IAS/Pfiser Independent Grant.</funding-statement></funding-group><funding-group xml:lang="en"><funding-statement>“LLC Amgen”, “Sanofi”, “AstraZeneca” and IAS/ Pfizer Independent Grant</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Libby P, Ridker PM, Maseri A. Inflammation and Atherosclerosis Circulation. 2002;105:1135-1143 DOI: 10.1161/hc0902/104353</mixed-citation><mixed-citation xml:lang="en">Libby P, Ridker PM, Maseri A. Inflammation and Atherosclerosis Circulation. 2002;105:1135-1143https://doi.org/10.1161/hc0902/104353</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Tsiantoulas D, Diehl CJ, Witztum JL, Binder CJ. B cells and humoral immunity in atherosclerosis. Circ Res. 2014; 114(11):1743-56. DOI: 10.1161/CIRCRESAHA.113.301145.</mixed-citation><mixed-citation xml:lang="en">Tsiantoulas D, Diehl CJ, Witztum JL, Binder CJ. B cells and humoral immunity in atherosclerosis. Circ Res. 2014; 114(11):1743-56. https://doi.org/10.1161/CIRCRESAHA.113.301145.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Афанасьева О.И., Пылаева Е.А., Клесарева Е.А.и др. Липопротеид(а) [Лп(а)], аутоантитела к Лп(а) и циркулирующие субпопуляции Т-лимфоцитов как независимые факторы риска атеросклероза коронарных артерий. Терапевтический архив, 2016;9:31-38. DOI: 10.17116/terarkh201688931-38</mixed-citation><mixed-citation xml:lang="en">Afanasieva O.I., Pylaeva E.A., Rltsareva E.A., et al. Lipoprotein(a), its autoantibodies, and circulating T lymphocyte subpopulations as independent risk factors for coronary artery atherosclerosis Therapeutic archive, 2016;9:31-38. Russian https://doi.org/10.17116/terarkh201688931-38</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Miller Y. I., Tsimikas S. Lipoprotein oxidation and modification. In: Ballantyne С.M. editor, Clinical Lipidology: a companion to Braunwald's heart disease Elsevier Unc. 2009;93-110.</mixed-citation><mixed-citation xml:lang="en">Miller Y. I., Tsimikas S. Lipoprotein oxidation and modification. In: Ballantyne С.M. editor, Clinical Lipidology: a companion to Braunwald's heart disease Elsevier Unc. 2009;93-110.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Hirayama S., Miida T. Small dense LDL: An emerging risk factor for cardiovascular disease. Clin Chim Acta 2012; 414:215–224. DOI:10.1016/j.cca.2012.09.010</mixed-citation><mixed-citation xml:lang="en">. Hirayama S., Miida T. Small dense LDL: An emerging risk factor for cardiovascular disease. Clin Chim Acta 2012; 414:215-224. https://doi.org/10.1016/j.cca.2012.09.010</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Yu XH, Fu YC, Zhang DW, Yin K, Tang CK. Foam cells in atherosclerosis. Clin Chim Acta. 2013 23;424:245-52. DOI: 10.1016/j.cca.2013.06.006.</mixed-citation><mixed-citation xml:lang="en">Yu XH, Fu YC, Zhang DW, Yin K, Tang CK. Foam cells in atherosclerosis. Clin Chim Acta. 2013 23;424:245-52. https://doi.org/10.1016/j.cca.2013.06.006.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Scipione CA, Koschinsky ML, Boffa MB. Lipoprotein(a) in clinical practice: New perspectives from basic and translational science. Crit Rev Clin Lab Sci. 2018;55(1):33-54. DOI: 10.1080/10408363.2017.1415866.</mixed-citation><mixed-citation xml:lang="en">Scipione CA, Koschinsky ML, Boffa MB. Lipoprotein(a) in clinical practice: New perspectives from basic and translational science. Crit Rev Clin Lab Sci. 2018;55(1):33-54.https://doi.org/10.1080/10408363.2017.1415866.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Афанасьева О.И., Клесарева Е.А., Левашов П.А., и др. Аутоантитела против липопротеида(а) у больных с ишемической болезнью сердца. Кардиология. 2014;Т.54:№ 6:С. 4-8.</mixed-citation><mixed-citation xml:lang="en">Afanasieva OI, Klesareva EA, Levashov PA, et al. Autoantibodies against lipoprotein (a) in patients with ischemic heart disease. Cardiology. 2014; 54:(6):4-8. Russian</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Gonçalves I, Cherfan P, Söderberg I, Nordin Fredrikson G, Jonasson L. Effects of simvastatin on circulating autoantibodies to oxidized LDL antigens: relation with immune stimulation markers. Autoimmunity. 2009 Mar;42(3):203-8. doi: 10.1080/08916930802668602</mixed-citation><mixed-citation xml:lang="en">Gonçalves I, Cherfan P, Söderberg I, Nordin Fredrikson G, Jonasson L. Effects of simvastatin on circulating autoantibodies to oxidized LDL antigens: relation with immune stimulation markers. Autoimmunity. 2009 Mar;42(3):203-8. https://doi.org/10.1080/08916930802668602</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Афанасьева О.И., Адамова И.Ю., Беневоленская Г.Ф., и соавт. Иммуноферментный метод определения липопротеида (а). Бюллетень экспериментальной биологии и медицины.- 1995; № 10:C398-401.</mixed-citation><mixed-citation xml:lang="en">Afanasieva OI, Adamova I.Yu., Benevolenskaya GF, et al. Immunoenzyme method for determining the lipoprotein (a). Bulletin of Experimental Biology and Medicine, 1995;10:398-401. Russian</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Уткина Е.А., Афанасьева О.И., Ежов М.В., Артемьева Н.В., Матчин Ю.Г., Байда С.М., Адамова И.Ю., Покровский С.Н. Связь различных подфракций липопротеидов с коронарным атеросклерозом у мужчин среднего возраста, получавших терапию статинами Кардиологический вестник. 2014;Т.IX: №1:С.68-76.</mixed-citation><mixed-citation xml:lang="en">Utkina EA, Afanasyeva OI, Ezhov MV, et. al. The connection of various lipofrotein subfractions with coronary atherosclerosis in middle-aged men receiving statin therapy. Kardiologicheskij Vestnik . 2014; IX:(1):68-76. Russian</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Dahlen G.H. Incidence of Lp(a) among populations. In: Scanu AM, editor. Lipoprotein(a). New York: Academic Press; 1990;151-173</mixed-citation><mixed-citation xml:lang="en">Dahlen G.H. Incidence of Lp(a) among populations. In: Scanu AM, editor. Lipoprotein(a). New York: Academic Press; 1990;151-173</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Ланкин В.З., Афанасьева О.И., Коновалова Г.Г., Клесарева Е.А., Уткина Е.А., Тихазе А.К., Кумскова Е.М., Покровский С.Н. Окисляемость липопротеидов низкой плотности и липопротеида (а)/ Кардиологический вестник. 2014; Т. IX: № 3: С. 84-88</mixed-citation><mixed-citation xml:lang="en">Lankin VZ, Afanasyeva OI, Konovalova GG, http://et.al. Oxidability of low-density lipoprotein and lipoprotein (a) / Kardiologicheskij Vestnik . 2014;IX(3):84-88. Russian</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Miller Y, Tsimikas S. Oxidation-specific epitopes as targets for biotheranostic applications in humans: Biomarkers, molecular imaging and therapeutics Curr Opin Lipidol. 2013; 24(5):426–437. DOI: 10.1097/MOL.0b013e328364e85a</mixed-citation><mixed-citation xml:lang="en">Miller Y, Tsimikas S. Oxidation-specific epitopes as targets for biotheranostic applications in humans: Biomarkers, molecular imaging and therapeutics Curr Opin Lipidol. 2013; 24(5):426-437.https://doi.org/10.1097/MOL.0b013e328364e85a</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Tsimikas S, Willeit P, Willeit J, Santer P, Mayr M, Xu Q, Mayr A, Witztum JL, Kiechl S. Oxidation-specific biomarkers, prospective 15-year cardiovascular and stroke outcomes, and net reclassification of cardiovascular events. J Am Coll Cardiol. 2012;60(21):2218-29. DOI: 10.1016/j.jacc.2012.08.979</mixed-citation><mixed-citation xml:lang="en">Tsimikas S, Willeit P, Willeit J, Santer P, Mayr M, Xu Q, Mayr A, Witztum JL, Kiechl S. Oxidation-specific biomarkers, prospective 15-year cardiovascular and stroke outcomes, and net reclassification of cardiovascular events. J Am Coll Cardiol. 2012;60(21):2218-29. https://doi.org/10.1016/j.jacc.2012.08.979</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Prasad A, Clopton P, Ayers C, Khera A, de Lemos JA, Witztum JL, Tsimikas S. Relationship of Autoantibodies to MDA-LDL and ApoB-Immune Complexes to Sex, Ethnicity, Subclinical Atherosclerosis, and Cardiovascular Events. Arterioscler Thromb Vasc Biol. 2017;37(6):1213-1221. DOI: 10.1161/ATVBAHA.117.309101</mixed-citation><mixed-citation xml:lang="en">Prasad A, Clopton P, Ayers C, Khera A, de Lemos JA, Witztum JL, Tsimikas S. Relationship of Autoantibodies to MDA-LDL and ApoB-Immune Complexes to Sex, Ethnicity, Subclinical Atherosclerosis, and Cardiovascular Events. Arterioscler Thromb Vasc Biol. 2017;37(6):1213-1221.https://doi.org/10.1161/ATVBAHA.117.309101</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Enkhmaa B, Anuurad E, Berglund L. Lipoprotein (a): impact by ethnicity and environmental and medical conditions. J Lipid Res. 2016;57(7):1111-25. DOI: 10.1194/jlr.R051904.</mixed-citation><mixed-citation xml:lang="en">Enkhmaa B, Anuurad E, Berglund L. Lipoprotein (a): impact by ethnicity and environmental and medical conditions. J Lipid Res. 2016;57(7):1111-25. https://doi.org/10.1194/jlr.R051904.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Taleb A, Zhao W, Shahzada A, Rasheed A, Binder CJ, Witztum JL, Danesh J, Rader D J, Tsimikas S, Saleheen D. Increased levels of IgM autoantibodies to oxidation-specific epitopes are inversely associated with coronary heart disease: analyses of data from 204,257 participants. Circulation. 2015;132:A14351.</mixed-citation><mixed-citation xml:lang="en">Taleb A, Zhao W, Shahzada A, Rasheed A, Binder CJ, Witztum JL, Danesh J, Rader D J, Tsimikas S, Saleheen D. Increased levels of IgM autoantibodies to oxidation-specific epitopes are inversely associated with coronary heart disease: analyses of data from 204,257 participants. Circulation. 2015;132:A14351</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
